Kerry-Anne Rye

发表

HDL function as a predictor of coronary heart disease events: time to re-assess the HDL hypothesis?

K. Rye, K. Ong, Kerry-Anne Rye, 2015, The lancet. Diabetes & endocrinology.

HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells

Praveen Sethupathy, P. Sethupathy, P. Barter, 2014, Nature Communications.

Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa.

P. Barter, A. Marais, K. Rye, 2008, Atherosclerosis.

HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology

Jean-Claude Tardif, Frank M. Sacks, Robert A. Hegele, 2018, Nature Reviews Cardiology.

Aerobic, resistance or combined training: A systematic review and meta-analysis of exercise to reduce cardiovascular risk in adults with metabolic syndrome.

Jeanette M. Thom, J. Thom, K. Rye, 2018, Atherosclerosis.

Apolipoprotein E activates the low-activity form of human phospholipid transfer protein.

Christian Ehnholm, Matti Jauhiainen, H. Lankinen, 2005, Biochemical and biophysical research communications.

High-density lipoprotein (HDL) transport in the metabolic syndrome: application of a new model for HDL particle kinetics.

P Hugh R Barrett, Dick C Chan, Gerald F Watts, 2006, The Journal of clinical endocrinology and metabolism.

Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) Trial (Retraction of vol 59, pg 1778, 2012)

Philip J. Barter, Gilles Lambert, Kerry-Anne Rye, 2013 .

High-Density Lipoproteins Neutralize C-Reactive Protein Proinflammatory Activity

J. Gamble, M. Vadas, P. Barter, 2004, Circulation.

Apolipoprotein A-II Inhibits High Density Lipoprotein Remodeling and Lipid-poor Apolipoprotein A-I Formation*

P. Barter, K. Rye, L. Curtiss, 2003, Journal of Biological Chemistry.

Phosphorylation of apolipoprotein-E at an atypical protein kinase CK2 PSD/E site in vitro.

G. Halliday, M. Raftery, K. Rye, 2005, Biochemistry.